现代化的心脏抗失律药物分类:其在临床实践中的应用
Ming Lei1, Lin Wu2, Derek A Terrar1
1Department of Pharmacology, University of Oxford, Oxford, United Kingdom.
Heart rhythm
|April 5, 2025
概括
一个修订的沃恩·威廉姆斯分类简化了心律不整的抗心律不整药物 (AAD) 治疗. 这个更新的方案侧重于临床使用的药物,保留了原始框架,同时提高了更好的患者管理的可访问性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 电子生理学 电子生理学
背景情况:
- 心律不整是一个重要的公共卫生问题,需要有效的药物治疗.
- 1970年沃恩·威廉姆斯 (VW) 对抗节律障碍药物 (AADs) 的分类是基础性的,但由于进展,需要更新.
- 现有的分类需要适应当前的临床实践和药物开发.
研究的目的:
- 为了改善临床实践的可访问性,调整一个全面的现代化AAD分类.
- 专注于目前正在临床使用的关键ADS,保留核心VW方案.
- 为AAD管理提供灵活和最新的框架.
主要方法:
- 基于当前的电生理学理解,开发了一个简化的ADD分类方案.
- 专注于已建立的AAD和已批准的非标签使用药物,不包括正在研究的新药 (IND).
- 保持基于心肌细胞点和功能机制的概念框架.
主要成果:
- 通过专注于目前使用的药物,调整后的方案提高了临床医生的可访问性.
- 它保留了既定的大众汽车分类,同时结合了现代电生理学的见解.
- 该分类是灵活的,允许药物在多个类别和未来的添加.
结论:
- 适应的AAD分类提供了现代化,简化和临床专注的方法来管理心律失常.
- 该方案保留了经典大众分类的优势,同时仍然适应未来的治疗发展.
- 它有助于在临床环境中更好地理解和应用AAD.
关键词:
抗心律失常药物 抗心律失常药物卡2+) 恒常状态心脏节律不整的心脏节律不整.离子通道的离子通道迈尔斯·沃恩·威廉姆斯·威廉姆斯 (英语:Miles Vaughan Williams) 是一个著名的作家.更多相关视频
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
670
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
670
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
850
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
850
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
719
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
719
Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K
Heart Failure Drugs: Inotropic Agents
445
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
445


